Yasuhiro Oki
YOU?
Author Swipe
View article: The rationality problem for multinorm one tori
The rationality problem for multinorm one tori Open
In this paper, we study the rationality problem for multinorm one tori, a natural generalization of norm one tori. For multinorm one tori that split over finite Galois extensions with nilpotent Galois group, we prove that stable rationalit…
View article: Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma Open
Introduction: AZD0486 is a novel, IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE) with a low-affinity anti-CD3 moiety uniquely engineered to reduce cytokine release while maintaining potent antitumor cytotoxicity. AZD0486 is bein…
View article: On Tamagawa numbers of CM tori
On Tamagawa numbers of CM tori Open
We investigate the problem of computing Tamagawa numbers of CM tori.This problem arises naturally from the problem of counting polarized abelian varieties with commutative endomorphism algebras over finite fields, and polarized CM abelian …
View article: Cohomological properties of multinorm-one tori
Cohomological properties of multinorm-one tori Open
In this paper we investigate the Tate--Shafarevich group Sha^1(k, T) of a multinorm-one torus $T$ over a global field $k$. We establish a few functorial maps among cohomology groups and explore their relations. Using these properties and r…
View article: The Hasse norm principle for some non-Galois extensions of square-free degree
The Hasse norm principle for some non-Galois extensions of square-free degree Open
In this paper, we study the Hasse norm principle for some non-Galois extensions of number fields. Our main theorem is that for any square-free composite number $d$ which is divisible by at least one of $3$, $55$, $91$ or $95$, there exists…
View article: Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
In patients treated with vorinostat and everolimus, there was a longer median progression-free survival in patients with normal LDH compared to patients with high LDH (5.8 months, 4.4 - 7.2 vs. 1.6 months, 95% CI 1.3-1.9; P < 0.001).
View article: Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Clinical Study Protocol: A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients with Advanced Cancer
View article: Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
In patients treated with vorinostat and everolimus, there was a longer median progression-free survival in patients with normal albumin compared to patients with low albumin (5.8 months, 4.4 - 7.2 vs. 1.6 months, 95% CI 1.3-1.9; P < 0.001).
View article: Supplementary Figure 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Dose modifications: vorinostat and sirolimus
View article: Data from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Data from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Purpose:Preclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and Methods:During the dose-escalation study (ClinicalTrials.gov numb…
View article: Supplementary Figure 3 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 3 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Representative images of selected patients with therapy response.
View article: Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Protocol: Data Analysis of Patients Treated Off-protocol
View article: Data from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Data from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Purpose:Preclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and Methods:During the dose-escalation study (ClinicalTrials.gov numb…
View article: Supplementary Figure 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Dose modifications: vorinostat and everolimus
View article: Supplementary Figure 4 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 4 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
In patients treated with vorinostat and sirolimus, there was a trend towards a longer median progression-free survival in patients with ECOG performance status 0 compared to ECOG 1 or 2 (not reached vs. 4.6 months, 95% CI 1.5-7.7; P = 0.06…
View article: Supplementary Figure 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Dose modifications: vorinostat and sirolimus
View article: Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
In patients treated with vorinostat and everolimus, there was a longer median progression-free survival in patients with normal LDH compared to patients with high LDH (5.8 months, 4.4 - 7.2 vs. 1.6 months, 95% CI 1.3-1.9; P < 0.001).
View article: Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Protocol: Data Analysis of Patients Treated Off-protocol
View article: Supplementary Figure 4 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 4 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
In patients treated with vorinostat and sirolimus, there was a trend towards a longer median progression-free survival in patients with ECOG performance status 0 compared to ECOG 1 or 2 (not reached vs. 4.6 months, 95% CI 1.5-7.7; P = 0.06…
View article: Supplementary Figure 3 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 3 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Representative images of selected patients with therapy response.
View article: Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
In patients treated with vorinostat and everolimus, there was a longer median progression-free survival in patients with normal albumin compared to patients with low albumin (5.8 months, 4.4 - 7.2 vs. 1.6 months, 95% CI 1.3-1.9; P < 0.001).
View article: Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Supplementary Table 1. Durations of dose interruptions in vorinostat and sirolimus arm; Supplementary Table 2. Durations of dose interruptions in vorinostat and everolimus arm
View article: Supplementary Figure 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Figure 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Dose modifications: vorinostat and everolimus
View article: Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Supplementary Table 1. Durations of dose interruptions in vorinostat and sirolimus arm; Supplementary Table 2. Durations of dose interruptions in vorinostat and everolimus arm
View article: Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma Open
Clinical Study Protocol: A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients with Advanced Cancer
View article: Data from Silencing of Bidirectional Promoters by DNA Methylation in Tumorigenesis
Data from Silencing of Bidirectional Promoters by DNA Methylation in Tumorigenesis Open
CpG island methylation within promoters is known to silence individual genes in cancer. The involvement of this process in silencing gene pairs controlled by bidirectional promoters is unclear. In a screen for hypermethylated CpG islands i…
View article: Supplementary Tables 1-2 from Silencing of Bidirectional Promoters by DNA Methylation in Tumorigenesis
Supplementary Tables 1-2 from Silencing of Bidirectional Promoters by DNA Methylation in Tumorigenesis Open
Supplementary Tables 1-2 from Silencing of Bidirectional Promoters by DNA Methylation in Tumorigenesis